Can-Fite BioPharma reports 9month net loss $5.98M vs. net loss of $7.15M

Reports revenues for the nine months ended September 30 were $590K compared to revenues of 610K for the same period in 2022. Revenues for the nine months ended September 30, and September 30, 2022 comprised of recognition of a portion of advance payments received under distribution agreements with Gebro, CKD, Cipher and Ewopharma. As of September 30, Can-Fite had cash and cash equivalents and short term deposits of $7.94M as compared to $7.98M at December 31, 2022. The decrease in cash during the nine months ended nine 30, 2023 is due to the ongoing operations of the Company which was offset by the Company’s fundraise during January 2023. During November 2023, Can-Fite raised approximately $3 million from the exercise of certain warrants